Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenzo Gerratana

Showing results (11-20 of 127) with videos related to

Pageof 13
Sort By:
BMC Cancer|May 22, 2025
Patient preferences for treatments in hormone receptor-positive/HER2-negative metastatic breast cancer in Italy: a discrete choice experiment studyGrazia Arpino, Carmine De Angelis, Lorenzo Gerratana, et al.
Breast (Edinburgh, Scotland)|December 21, 2024
Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancerBrenno Pastò, Riccardo Vida, Arianna Dri, et al.
The Oncologist|November 7, 2023
Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 TrialLorenzo Gerratana, Masha Kocherginsky, Andrew A Davis, et al.
International Review of Cell and Molecular Biology|September 22, 2023
Latest advances in clinical studies of circulating tumor cells in early and metastatic breast cancerLaura S Munoz-Arcos, Eleonora Nicolò, Mara S Serafini, et al.
International Journal of Molecular Sciences|July 13, 2019
Platinum Salts in Patients with Breast Cancer: A Focus on Predictive FactorsMattia Garutti, Giacomo Pelizzari, Michele Bartoletti, et al.
Breast (Edinburgh, Scotland)|April 6, 2025
Mapping breast cancer therapy with circulating tumor cells: The expert perspectiveLorenzo Gerratana, Caterina Gianni, Eleonora Nicolò, et al.
The Oncologist|May 29, 2015
Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?Marta Bonotto, Lorenzo Gerratana, Donatella Iacono, et al.
Cancer Treatment Reviews|October 28, 2017
Androgen receptor in estrogen receptor positive breast cancer: Beyond expressionDebora Basile, Marika Cinausero, Donatella Iacono, et al.
Targeted Oncology|May 2, 2024
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting SystemSara Cecco, Stefano Puligheddu, Michele Fusaroli, et al.
Cancer Treatment Reviews|November 12, 2018
Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalationGiacomo Pelizzari, Lorenzo Gerratana, Debora Basile, et al.
Pageof 13

Showing results (11-20 of 127) with videos related to

Sort By:
Pageof 13
BMC Cancer|May 22, 2025
Patient preferences for treatments in hormone receptor-positive/HER2-negative metastatic breast cancer in Italy: a discrete choice experiment studyGrazia Arpino, Carmine De Angelis, Lorenzo Gerratana, et al.
Breast (Edinburgh, Scotland)|December 21, 2024
Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancerBrenno Pastò, Riccardo Vida, Arianna Dri, et al.
The Oncologist|November 7, 2023
Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 TrialLorenzo Gerratana, Masha Kocherginsky, Andrew A Davis, et al.
International Review of Cell and Molecular Biology|September 22, 2023
Latest advances in clinical studies of circulating tumor cells in early and metastatic breast cancerLaura S Munoz-Arcos, Eleonora Nicolò, Mara S Serafini, et al.
International Journal of Molecular Sciences|July 13, 2019
Platinum Salts in Patients with Breast Cancer: A Focus on Predictive FactorsMattia Garutti, Giacomo Pelizzari, Michele Bartoletti, et al.
Breast (Edinburgh, Scotland)|April 6, 2025
Mapping breast cancer therapy with circulating tumor cells: The expert perspectiveLorenzo Gerratana, Caterina Gianni, Eleonora Nicolò, et al.
The Oncologist|May 29, 2015
Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?Marta Bonotto, Lorenzo Gerratana, Donatella Iacono, et al.
Cancer Treatment Reviews|October 28, 2017
Androgen receptor in estrogen receptor positive breast cancer: Beyond expressionDebora Basile, Marika Cinausero, Donatella Iacono, et al.
Targeted Oncology|May 2, 2024
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting SystemSara Cecco, Stefano Puligheddu, Michele Fusaroli, et al.
Cancer Treatment Reviews|November 12, 2018
Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalationGiacomo Pelizzari, Lorenzo Gerratana, Debora Basile, et al.
Pageof 13